cardioP Cancer Research Results
cardioP, cardioProtective: Click to Expand ⟱
| Source: |
| Type: |
CardioProtective
|
Scientific Papers found: Click to Expand⟱
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*antiOx↑, antioxidant potential and free radical scavenging activity.
*ROS↓,
*IronCh↑, Lipoic acid acts as a chelating agent for metal ions, a quenching agent for reactive oxygen species, and a reducing agent for the oxidized form of glutathione and vitamins C and E.
*cognitive↑, α-Lipoic acid enantiomers and its reduced form have antioxidant, cognitive, cardiovascular, detoxifying, anti-aging, dietary supplement, anti-cancer, neuroprotective, antimicrobial, and anti-inflammatory properties.
*cardioP↓,
AntiCan↑,
*neuroP↑,
*Inflam↓, α-Lipoic acid can reduce inflammatory markers in patients with heart disease
*BioAv↓, bioavailability in its pure form is low (approximately 30%).
*AntiAge↑, As a dietary supplements α-lipoic acid has become a common ingredient in regular products like anti-aging supplements and multivitamin formulations
*Half-Life↓, it has a half-life (t1/2) of 30 min to 1 h.
*BioAv↝, It should be stored in a cool, dark, and dry environment, at 0 °C for short-term storage (few days to weeks) and at − 20 °C for long-term storage (few months to years).
other↝, Remarkably, neither α-lipoic acid nor dihydrolipoic acid can scavenge hydrogen peroxide, possibly the most abundant second messenger ROS, in the absence of enzymatic catalysis.
EGFR↓, α-Lipoic acid inhibits cell proliferation via the epidermal growth factor receptor (EGFR) and the protein kinase B (PKB), also known as the Akt signaling, and induces apoptosis in human breast cancer cells
Akt↓,
ROS↓, α-Lipoic acid tramps the ROS followed by arrest in the G1 phase of the cell cycle and activates p27 (kip1)-dependent cell cycle arrest via changing of the ratio of the apoptotic-related protein Bax/Bcl-2
TumCCA↑,
p27↑,
PDH↑, α-Lipoic acid drives pyruvate dehydrogenase by downregulating aerobic glycolysis and activation of apoptosis in breast cancer cells, lactate production
Glycolysis↓,
ROS↑, HT-29 human colon cancer cells; It was concluded that α-lipoic acid induces apoptosis by a pro-oxidant mechanism triggered by an escalated uptake of mitochondrial substrates in oxidizable form
*eff↑, Several studies have found that combining α-lipoic acid and omega-3 fatty acids has a synergistic effect in slowing functional and cognitive decline in Alzheimer’s disease
*memory↑, α-lipoic acid inhibits brain weight loss, downregulates oxidative tissue damage resulting in neuronal cell loss, repairs memory and motor function,
*motorD↑,
*GutMicro↑, modulates the gut microbiota without reducing the microbial diversity (
*Inflam↓, Diclofenac is an NSAID belonging to the family of phenylacetic acids and acts to decrease inflammation as other class drugs do.
*COX1↓, Diclofenac employs its action by inhibiting the activity of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) by inhibiting the synthesis of prostanoids such as prostaglandin-E2 (PGE2), prostacyclins, and thromboxanes,
*COX2↓,
*PGE2↓,
*TXA2↓,
*BioAv↑, When orally administered, diclofenac is absorbed rapidly and binds to albumin in the plasma.
*Dose↝, Oral diclofenac sodium can be administered in delayed-release or immediate-release tablets in 25 to 150 mg tablets to achieve a total daily dose of 100-150 mg per day.
*cardioP↓, it has an increased associated risk of cardiovascular events
*cardioP↓, One of the most common nonsteroidal anti-inflammatory drugs (NSAIDs) used worldwide, diclofenac (DIC), has been linked to increased risk of cardiovascular disease (CVD)
*ROS↑, DIC increased ROS production and cell death in H9c2 cells
MMP↓, DIC inhibited mitochondrial Complex III, a major source of ROS, and impaired mitochondrial membrane potential suggesting that mitochondria are the major sites of ROS generation.
compIII↓,
*Pain↓, Diclofenac is a widely used medicine for relieving pain and inflammation, particularly in painful conditions such as arthritis.
*Inflam↓,
*AntiArt↑,
*cardioP↓, the overall number of heart attacks in people at moderate risk would be expected to increase by around 3 cases per year for every 1,000 people treated with diclofenac (to 11 per 1,000 people per year).
Showing Research Papers: 1 to 4 of 4
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↓, 1, ROS↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
compIII↓, 1, MMP↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
Glycolysis↓, 1, PDH↑, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, p27↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
TumCCA↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
EGFR↓, 1,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 1,
Total Targets: 13
Pathway results for Effect on Normal Cells:
NA, unassigned(tgid=0) ⓘ
AntiArt↑, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 1, ROS↓, 1, ROS↑, 1,
Metal & Cofactor Biology(tgid=2) ⓘ
IronCh↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
TXA2↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
COX1↓, 1, COX2↓, 1, Inflam↓, 3, PGE2↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 1, BioAv↑, 1, BioAv↝, 1, Dose↝, 1, eff↑, 1, Half-Life↓, 1,
Clinical Biomarkers(tgid=22) ⓘ
GutMicro↑, 1,
Functional Outcomes(tgid=23) ⓘ
AntiAge↑, 1, cardioP↓, 4, cognitive↑, 1, memory↑, 1, motorD↑, 1, neuroP↑, 1, Pain↓, 1,
Total Targets: 24
Scientific Paper Hit Count for: cardioP, cardioProtective
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1188 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page